Collegium Pharmaceutical Inc (COLL)vsViatris Inc (VTRS)
COLL
Collegium Pharmaceutical Inc
$24.95
+0.56%
HEALTHCARE · Cap: $770.98M
VTRS
Viatris Inc
$20.67
-1.85%
HEALTHCARE · Cap: $23.90B
Smart Verdict
WallStSmart Research — data-driven comparison
Viatris Inc generates 1707% more annual revenue ($14.73B vs $815.19M). COLL leads profitability with a 4.7% profit margin vs -4.1%. COLL appears more attractively valued with a PEG of 0.72. COLL earns a higher WallStSmart Score of 58/100 (C).
COLL
Buy58
out of 100
Grade: C
VTRS
Hold40
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+88.3%
Fair Value
$384.11
Current Price
$24.95
$359.16 discount
Margin of Safety
-81.4%
Fair Value
$8.89
Current Price
$20.67
$11.78 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Growing faster than its price suggests
Reasonable price relative to book value
Strong operational efficiency at 22.9%
Reasonable price relative to book value
Areas to Watch
3.3% revenue growth
Smaller company, higher risk/reward
4.7% margin — thin
Earnings declined 29.0%
Expensive relative to growth rate
ROE of -2.9% — below average capital efficiency
Revenue declined 0.3%
Earnings declined 70.6%
Comparative Analysis Report
WallStSmart ResearchBull Case : COLL
The strongest argument for COLL centers on PEG Ratio, Price/Book, Operating Margin. PEG of 0.72 suggests the stock is reasonably priced for its growth.
Bull Case : VTRS
The strongest argument for VTRS centers on Price/Book.
Bear Case : COLL
The primary concerns for COLL are Revenue Growth, Market Cap, Profit Margin. Debt-to-equity of 2.75 is elevated, increasing financial risk. Thin 4.7% margins leave little buffer for downturns.
Bear Case : VTRS
The primary concerns for VTRS are PEG Ratio, Return on Equity, Revenue Growth.
Key Dynamics to Monitor
COLL profiles as a value stock while VTRS is a turnaround play — different risk/reward profiles.
VTRS carries more volatility with a beta of 0.87 — expect wider price swings.
COLL is growing revenue faster at 3.3% — sustainability is the question.
VTRS generates stronger free cash flow (329M), providing more financial flexibility.
Bottom Line
COLL scores higher overall (58/100 vs 40/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Collegium Pharmaceutical Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and markets pain management medications. The company is headquartered in Stoughton, Massachusetts.
Viatris Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Viatris Inc. is an American global healthcare company headquartered in Canonsburg, Pennsylvania.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?